X4 Pharmaceuticals, Inc
XFOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501697
In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 2 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding X4 Pharmaceuticals, Inc changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 42 | 1 | 79 | +38 |
| Shares | 16.2M | 2.91K | 89.4M | +73.3M (+453.5%) |
| Value | $55.3M | $9.97K | $357.7M | +$302.5M (+547.4%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (42)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (4)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Kingdon Capital Management, L.L.C. | 933,332 | $3.19M |
| Boothbay Fund Management, LLC | 343,963 | $1.18M |
| Renaissance Technologies LLC | 19,177 | $65.6K |
| TD Waterhouse Canada Inc. | 1,500 | $5.37K |
Not filed for Q4 2025 yet (1)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Point72 Asia (Singapore) Pte. Ltd. | 2,914 | $9.97K |